- BioChem Pharma has announced that it has received a US protection patent covering its once-daily, oral treatment lamivudine for chronic hepatitis B, until 2013. It has already received similar patents in Australia, Europe, Asia, and South Africa, with several others pending. Currently in Phase III clinical trials, it is expected that marketing applications will be filed in 1997. Lamivudine is also in trials as a once-daily oral pre- and post-transplant treatment for patients in end-stage liver disease, and who require a liver transplant as a result of chronic hepatitis B.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze